Search and Browse
Download
Enter Data
| Reaction Details | |||
|---|---|---|---|
 | Report a problem with these data | ||
| Target | Mitogen-activated protein kinase 14 | ||
| Ligand | BDBM50251921 | ||
| Substrate/Competitor | n/a | ||
| Meas. Tech. | ChEMBL_488009 (CHEMBL1013888) | ||
| IC50 | 11±n/a nM | ||
| Citation |  Laufer, SA; Hauser, DR; Domeyer, DM; Kinkel, K; Liedtke, AJ Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region. J Med Chem51:4122-49 (2008) [PubMed] Article | ||
| More Info.: | Get all data from this article, Assay Method | ||
| Mitogen-activated protein kinase 14 | |||
| Name: | Mitogen-activated protein kinase 14 | ||
| Synonyms: | CSAID-binding protein | CSBP | CSBP1 | CSBP2 | CSPB1 | Cytokine suppressive anti-inflammatory drug-binding protein | MAP kinase 14 | MAP kinase MXI2 | MAP kinase p38 alpha | MAPK 14 | MAPK14 | MAX-interacting protein 2 | MK14_HUMAN | MXI2 | Mitogen-activated protein kinase p38 alpha | SAPK2A | Stress-activated protein kinase 2a | p38 MAP kinase alpha/beta | ||
| Type: | Serine/threonine-protein kinase | ||
| Mol. Mass.: | 41286.76 | ||
| Organism: | Homo sapiens (Human) | ||
| Description: | Q16539 | ||
| Residue: | 360 | ||
| Sequence: |
| ||
| BDBM50251921 | |||
| n/a | |||
| Name | BDBM50251921 | ||
| Synonyms: | CHEMBL481749 | trans-4-{4-[2-Methylsulfanyl-4-(3-trifluoromethyl-phenyl)-1H-imidazol-5-yl]-pyridin-2-ylamino}-cyclohexanol | ||
| Type | Small organic molecule | ||
| Emp. Form. | C22H23F3N4OS | ||
| Mol. Mass. | 448.504 | ||
| SMILES | CSc1nc(c([nH]1)-c1cccc(c1)C(F)(F)F)-c1ccnc(N[C@H]2CC[C@H](O)CC2)c1 |r,wU:26.28,wD:23.24,(26.57,-40.06,;25.8,-38.72,;24.26,-38.72,;23.35,-39.96,;21.89,-39.48,;21.89,-37.94,;23.36,-37.47,;20.57,-37.16,;19.23,-37.92,;17.91,-37.15,;17.91,-35.6,;19.25,-34.84,;20.58,-35.62,;19.26,-33.3,;19.25,-31.76,;20.8,-33.3,;17.72,-33.31,;20.56,-40.24,;19.22,-39.47,;17.89,-40.24,;17.89,-41.78,;19.23,-42.55,;19.24,-44.09,;20.58,-44.86,;20.57,-46.4,;21.9,-47.16,;23.24,-46.39,;24.57,-47.16,;23.24,-44.85,;21.9,-44.08,;20.56,-41.78,)| | ||
| Structure | 
| ||